drugset / Trial / NCT01425814

Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

NCT01425814

Phase 2 Completed 87 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.

Timeline

Start
2011-08
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Abediterol Small molecule 0.625 ug Inhaled
Subject Abediterol Small molecule 2.5 ug Inhaled
Subject Abediterol Small molecule 5 ug Inhaled
Subject Abediterol Small molecule 10 ug Inhaled
Comparator Indacaterol Other / unclassified 150 ug Inhaled